Palatin Technologies Inc (fra:PTN) Share Price

Company Profile

Business description
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. It is also developing, dependent on resources for development activities, MC1R agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It has one operating segment life science.
Contact
301 Carnegie Center Drive
Suite 304
PrincetonNJ08540
USA
T: +1 609 495-2200
E: [email protected]
https://www.palatin.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
25

Recommended

Fear outweighs fundamentals as ASX share reaffirms outlook.

Nathan Zaia | 29 October 2026

We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.

Eric Compton, CFA | 29 October 2026

We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.

Malik Ahmed Khan, CFA | 29 October 2026

Index	Last price	Change	% Change
All Ordinaries	9,025.40	12.80	0.14%
CAC 40	7,969.42	0.58	-0.01%
DAX 40	25,818.21	221.47	-0.85%
Dow JONES (US)	51,770.31	572.25	-1.09%
FTSE 100	10,729.78	7.71	0.07%
HKSE	23,294.42	335.77	1.46%
NASDAQ	25,437.00	747.73	-2.86%
Nikkei 225	63,290.11	1,369.36	-2.12%
NZX 50 Index	13,797.00	86.83	0.63%
S&P 500	7,580.07	140.32	-1.82%
S&P/ASX 200	8,908.10	16.30	0.18%
SSE Composite Index	3,599.02	52.42	-1.44%